RhumbLine Advisers’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $427K | Sell |
306,926
-10,493
| -3% | -$14.4K | ﹤0.01% | 2710 |
|
|
2025
Q4 | $511K | Sell |
317,419
-41,252
| -12% | -$86.4K | ﹤0.01% | 2650 |
|
|
2025
Q3 | $979K | Sell |
358,671
-6,364
| -2% | -$21.2K | ﹤0.01% | 2256 |
|
|
2025
Q2 | $1.33M | Buy |
365,035
+82,969
| +29% | +$228K | ﹤0.01% | 2106 |
|
|
2025
Q1 | $542K | Buy |
282,066
+16,677
| +6% | +$34K | ﹤0.01% | 2526 |
|
|
2024
Q4 | $504K | Buy |
265,389
+22,513
| +9% | +$39.1K | ﹤0.01% | 2674 |
|
|
2024
Q3 | $321K | Sell |
242,876
-4,184
| -2% | -$5.59K | ﹤0.01% | 2986 |
|
|
2024
Q2 | $252K | Buy |
247,060
+242,134
| +4,915% | +$299K | ﹤0.01% | 3094 |
|
|
2024
Q1 | $9.01K | Hold |
4,926
| – | – | ﹤0.01% | 3888 |
|
|
2023
Q4 | $6.11K | Hold |
4,926
| – | – | ﹤0.01% | 3942 |
|
|
2023
Q3 | $5.62K | Hold |
4,926
| – | – | ﹤0.01% | 3961 |
|
|
2023
Q2 | $4.51K | Buy |
+4,926
| New | +$4.75K | ﹤0.01% | 4112 |
|
|
2022
Q2 | – | Sell |
-205,062
| Closed | -$147K | – | 3091 |
|
|
2022
Q1 | $147K | Sell |
205,062
-6,053
| -3% | -$12.9K | ﹤0.01% | 2823 |
|
|
2021
Q4 | $477K | Buy |
211,115
+805
| +0.4% | +$2.19K | ﹤0.01% | 2527 |
|
|
2021
Q3 | $606K | Buy |
210,310
+7,351
| +4% | +$21K | ﹤0.01% | 2452 |
|
|
2021
Q2 | $769K | Buy |
202,959
+28,718
| +16% | +$96.7K | ﹤0.01% | 2361 |
|
|
2021
Q1 | $590K | Sell |
174,241
-14,840
| -8% | -$53.5K | ﹤0.01% | 2408 |
|
|
2020
Q4 | $529K | Buy |
189,081
+13,065
| +7% | +$38.1K | ﹤0.01% | 2420 |
|
|
2020
Q3 | $442K | Sell |
176,016
-33,183
| -16% | -$291K | ﹤0.01% | 2341 |
|
|
2020
Q2 | $2.84M | Sell |
209,199
-5,492
| -3% | -$56.8K | ﹤0.01% | 1532 |
|
|
2020
Q1 | $1.63M | Buy |
214,691
+30,789
| +17% | +$240K | ﹤0.01% | 1651 |
|
|
2019
Q4 | $1.16M | Buy |
183,902
+6,644
| +4% | +$31.6K | ﹤0.01% | 2008 |
|
|
2019
Q3 | $695K | Buy |
177,258
+16,059
| +10% | +$68.8K | ﹤0.01% | 2203 |
|
|
2019
Q2 | $780K | Buy |
161,199
+48,899
| +44% | +$278K | ﹤0.01% | 2165 |
|
|
2019
Q1 | $920K | Sell |
112,300
-9,097
| -7% | -$62.4K | ﹤0.01% | 2076 |
|
|
2018
Q4 | $671K | Buy |
121,397
+76,163
| +168% | +$596K | ﹤0.01% | 2162 |
|
|
2018
Q3 | $399K | Sell |
45,234
-2,413
| -5% | -$21.6K | ﹤0.01% | 2368 |
|
|
2018
Q2 | $476K | Buy |
47,647
+6,605
| +16% | +$66.1K | ﹤0.01% | 2327 |
|
|
2018
Q1 | $391K | Buy |
41,042
+270
| +0.7% | +$3.78K | ﹤0.01% | 2317 |
|
|
2017
Q4 | $606K | Sell |
40,772
-3,993
| -9% | -$66.2K | ﹤0.01% | 2162 |
|
|
2017
Q3 | $881K | Buy |
44,765
+3,255
| +8% | +$50K | ﹤0.01% | 2036 |
|
|
2017
Q2 | $596K | Buy |
41,510
+518
| +1% | +$6.57K | ﹤0.01% | 2209 |
|
|
2017
Q1 | $377K | Buy |
40,992
+1,266
| +3% | +$12.4K | ﹤0.01% | 2387 |
|
|
2016
Q4 | $414K | Sell |
39,726
-6,815
| -15% | -$58.7K | ﹤0.01% | 2320 |
|
|
2016
Q3 | $421K | Buy |
46,541
+710
| +2% | +$6.04K | ﹤0.01% | 2300 |
|
|
2016
Q2 | $343K | Buy |
45,831
+923
| +2% | +$8.06K | ﹤0.01% | 2444 |
|
|
2016
Q1 | $405K | Buy |
44,908
+12,110
| +37% | +$98.2K | ﹤0.01% | 2360 |
|
|
2015
Q4 | $424K | Buy |
32,798
+1,010
| +3% | +$10.3K | ﹤0.01% | 2349 |
|
|
2015
Q3 | $307K | Buy |
31,788
+1,848
| +6% | +$17K | ﹤0.01% | 2519 |
|
|
2015
Q2 | $308K | Buy |
+29,940
| New | +$255K | ﹤0.01% | 2636 |
|
Other funds holding AKBA
VCM
VPM
RhumbLine Advisers's AKBA Position: Q1 2026 in Review
RhumbLine Advisers reduced its Akebia Therapeutics (AKBA) stake by 3.3% in Q1 2026, selling an estimated $14.4K and leaving 306,926 shares worth $427K. The position accounts for ﹤0.01% of the portfolio, ranked #2710.
RhumbLine Advisers first reported a position in AKBA in Q2 2015 and has held it in 40 quarters since. The position peaked at $2.84M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- RhumbLine Advisers held 306,926 shares of Akebia Therapeutics worth $427K as of Q1 2026.
- RhumbLine Advisers sold 10,493 Akebia Therapeutics shares in Q1 2026, an estimated $14.4K.
- Akebia Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2710 holding.
- RhumbLine Advisers first reported a position in Akebia Therapeutics in Q2 2015 and has held it in 40 quarters since.
- RhumbLine Advisers's Akebia Therapeutics position peaked at $2.84M in Q2 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.